Financial Projections - The expected revenue for the first half of 2024 is between 363.04 million and 414.91 million CNY, representing a year-on-year decline of 20% to 30% from 518.63 million CNY[6] - The net profit attributable to shareholders is projected to be between 8.51 million and 12.77 million CNY, indicating a year-on-year decrease of 85% to 90% from 85.14 million CNY[6] - The net profit after deducting non-recurring gains and losses is expected to be between 4.57 million and 6.85 million CNY, reflecting a year-on-year decline of 91% to 94% from 76.14 million CNY[6] - The net cash flow from operating activities is projected to be between -113.40 million and -102.06 million CNY, with a year-on-year increase of 0% to 10%[6] - The basic earnings per share are expected to be between 0.06 CNY and 0.02 CNY, down from 0.21 CNY per share in the same period last year[6] - The detailed financial data for the first half of 2024 will be disclosed in the half-year report[8] Strategic Focus - The company is focusing on three major development directions: healthcare, digital governance, and smart cities, while enhancing R&D in AI, data elements, and blockchain[3] - The company will continue to adhere to its core strategy of "healthcare + smart cities" in the second half of 2024[7] Operational Challenges - The company anticipates stable growth in orders, but project implementation and acceptance cycles have been extended, leading to revenue decline and increased costs[11] Information Disclosure - The board guarantees the accuracy and completeness of the disclosed information, with no false records or misleading statements[10]

证券代码：002777 证券简称：久远银海 公告编号：2024-020 四川久远银海软件股份有限公司 关于关联交易的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、关联交易概述 1．关联交易的主要内容 根据近日中国工程物理研究院下属单位发布的成交通知书，四川久远银海软件股份有 限公司（以下简称"公司"）控股子公司四川兴政信息技术有限公司确定为"XX 软件采 购合同"供应商，拟与中国工程物理研究院下属单位签订合同，合同总金额预计 1，330.00 万元。 2．交易各方关联关系 3．关联交易审议情况 2024 年 7 月 11 日，公司独立董事就本次关联交易召开第六届董事会独立董事第四次 专门会议，以 3 票赞成、0 票反对、0 票弃权审议通过了《关于关联交易的议案》，同意 将该议案提交公司董事会审议。 公司于 2024 年 7 月 11 日召开第六届董事会第五次会议，以 5 票赞成、0 票反对、0 票弃权、4 票回避审议通过了《关于关联交易的议案》。公司董事李海燕女士、宋小沛先 生、袁宗宣先生和陈泉根先生为关联董事，对该议案回避表决。 4．本次关联交易 ...

四川久远银海软件股份有限公司 第六届董事会第五次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 四川久远银海软件股份有限公司（以下简称"公司"）第六届董事会第五次会议于2024年7 月11日以通讯方式召开，会议应出席表决的董事9人，实际出席表决的董事9人。会议的召开符 合《中华人民共和国公司法》、《公司章程》和《公司董事会议事规则》等规范性文件的有关规 定。经会议审议并表决，决议如下： 证券代码：002777 证券简称：久远银海 公告编号： 2024-019 关联董事宋小沛、李海燕、袁宗宣、陈泉根回避表决本议案。 独立董事事前召开了第六届董事会独立董事第三次专门会议并形成了决议。 表决结果：5票同意，0 票反对，0 票弃权，4票回避。该议案已通过。 特此公告。 三、备查文件 1、经公司与会董事签字的《四川久远银海软件股份有限公司第六届董事会第五次会议决 议》； 2、公司第六届董事会独立董事第四次专门会议决议。 特此公告。 二、董事会会议审议情况 会议以记名投票方式对各项议案进行表决，审议通过如下议案： （一）、《关于关联 ...

四川久远银海软件股份有限公司 第六届董事会独立董事第四次专门会议决议 本次关联交易的实施符合公司实际经营情况，符合公司与全体股东的利益， 不存在公司向关联方利益输送的情形，公司经营不会因此对关联方形成依赖，不 会影响公司的业务独立性，也不存在损害公司全体股东利益的情形。 根据《深圳证券交易所股票上市规则》，本次交易对手方中国工程物理研究 院下属单位为公司实际控制人下属单位，本次交易构成关联交易。本次交易不构 成《上市公司重大资产重组管理办法》规定的重大资产重组。 因此，我们同意将与本次交易相关的议案提交公司第六届董事会第五次会议 审议，在审议上述关联交易的议案时，关联董事应回避表决。 全体独立董事本着认真、负责的态度，在认真阅读公司提供的资料，听取有 关人员的汇报并详细了解有关情况后，经出席会议的独立董事审议和表决，形成 以下决议： 一、审议通过《关于关联交易的议案》 议案具体内容详见《证券时报》、《中国证券报》、《上海证券报》、《证 券日报》和巨潮资讯网（www.cninfo.com.cn）上披露的《四川久远银海软件股份 有限公司关于关联交易的公告》（公告编号2024-020）。 表决结果：同意3票，反对0 ...

2023 年年度权益分派实施公告 一、股东大会审议通过利润分配方案情况 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 四川久远银海软件股份有限公司（下称"公司"或"本公司"）2023年年度权益分 派方案已获2024年4月23日召开的公司2023年年度股东大会审议通过，具体内容详见 2024年4月3日及2024年4月24日公司在巨潮资讯网披露的《四川久远银海软件股份有限 公司2023年度利润分配预案的公告》（公告编号：2024-005）、《四川久远银海软件 股份有限公司2023年年度股东大会决议的公告》（公告编号：2024-011）。现将权益 分派事宜公告如下： 1.2024 年 4 月 23 日，公司召开 2023 年年度股东大会审议通过的 2023 年度利润分 配预案为: 以总股本 408,231,038 股为基数，向全体股东每 10 股派发现金红利 1.20 元 （含税），共分配现金红利 48,987,724.56 元，剩余未分配利润结转以后年度。不送红 股，不以公积金转增股本。 证券代码：002777 证券简称：久远银海 公告编号：2024-016 ...

Investment Rating - The report maintains a "Buy" rating for the company with a 12-month target price of 17.9 yuan [70][76] Core Views - The company is a leading smart livelihood service provider in China, focusing on three strategic directions: medical and healthcare, digital government, and smart cities [95][97] - The company has a stable equity structure, with the Chinese Academy of Engineering Physics as the actual controller, holding 38.31% of the shares [120] - The company's revenue and net profit have shown a recovery trend, with 2023 revenue reaching 1.347 billion yuan, a year-on-year increase of 5.01%, and net profit of 168 million yuan [124] - The company's main revenue sources are medical and healthcare, and smart city and digital government businesses, accounting for over 90% of total revenue [6] - The company has a leading position in the medical and healthcare informationization market, with its market share ranking second in the domestic medical insurance IT market [16][80] Business Segments Medical and Healthcare - The company's medical and healthcare business covers 23 provinces, serving over 160,000 medical insurance institutions, and has a leading position in the DRG/DIP payment reform market [80][142] - The company's medical health business covers 20 provinces and over 2,800 hospitals, providing solutions for high-quality hospital development [80] - The company is actively involved in the construction of medical consortia, providing integrated solutions for smart hospitals, smart medical consortia, and internet healthcare [53][142] - The company is a pioneer in medical insurance data elements, actively building data zones and optimizing data governance in Sichuan and Yunnan provinces [32][80] Digital Government and Smart Cities - The company's digital government business includes human resources and social security, housing finance, civil affairs, market supervision, and other areas, covering 21 provinces [97] - The company's smart city business focuses on building city-level core platforms, participating in the construction of "Digital Chongqing" and "Smart Rongcheng" [111] - In 2023, the company's smart city and digital government business revenue was 618 million yuan, and it is expected to grow to 668 million yuan, 748 million yuan, and 834 million yuan in 2024-2026 [44][111] Industry Trends - The medical and healthcare informationization market is expanding, with the domestic medical IT market expected to reach 35.75 billion yuan by 2028, and the medical insurance IT market expected to reach 8.15 billion yuan [80][157] - The DRG/DIP payment reform is driving market growth, with the overall market size expected to reach 18.174 billion yuan by 2024 [80] - The construction of medical consortia is accelerating, with the goal of achieving full coverage of tightly-knit county medical consortia by 2027 [26][142] - The medical insurance data element market is expected to grow rapidly, with the medical big data solutions market expected to reach 57.7 billion yuan by 2024 [57][149] Financial Performance - The company's revenue in 2023 was 1.347 billion yuan, a year-on-year increase of 5.01%, and net profit was 168 million yuan [124] - The company's gross profit margin has been under pressure due to economic conditions, dropping to 47.6% in 2023, but the gross profit margin of the smart city and digital government business has increased to 54.4% [125][126] - The company's R&D investment in 2023 was 152 million yuan, with an R&D expense ratio of 11.31% [8] - The company's operating cash flow in 2023 was 188.38 million yuan, and net profit was 178.73 million yuan [48]

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 25.65 CNY, compared to the current price of 19.21 CNY [1][5]. Core Insights - The company achieved a revenue of 1.347 billion CNY in 2023, representing a year-on-year growth of 5.01%. However, the net profit attributable to shareholders decreased by 8.83% to 168 million CNY, and the net profit excluding non-recurring items fell by 20.61% to 135 million CNY [1][5]. - In Q1 2024, the company reported a revenue of 196 million CNY, a 4.18% increase year-on-year, but the net profit attributable to shareholders dropped by 19.80% to 13 million CNY, with a 28.25% decline in net profit excluding non-recurring items to 10 million CNY [1][5]. - The company is actively exploring opportunities in healthcare data elements and AI applications, which are expected to drive significant growth in the future [5]. Financial Performance Summary - In 2023, the company's operating cash flow net amount reached 188 million CNY, a substantial increase of 401.83% year-on-year, with cash received from sales and services growing by 20.52% [5]. - The gross profit margin for 2023 was 47.61%, down 7.63 percentage points from the previous year, while the gross profit margin for Q4 2023 was 44.69%, a decrease of 6.14 percentage points year-on-year [5]. - The company forecasts revenues of 1.479 billion CNY, 1.738 billion CNY, and 2.028 billion CNY for 2024, 2025, and 2026, respectively, with net profits projected at 232 million CNY, 288 million CNY, and 348 million CNY for the same years [5][20].

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative price increase of over 15% against the benchmark index within the next 6 to 12 months [9]. Core Insights - The company has shown strong growth in its medical insurance business, with revenue reaching 1.347 billion yuan in 2023, a year-on-year increase of 5.01%. However, the net profit decreased to 168 million yuan, reflecting a decline of 9% year-on-year [13]. - The company is accelerating its data factor business, which is expected to open new growth opportunities. The medical insurance data factor business has already covered multiple provinces and cities, contributing significantly to revenue growth [13]. - The operating cash flow has improved, indicating better operational conditions. The company is actively exploring data factor services, which are expected to become a major source of income while maintaining good growth potential [13]. Financial Summary - Revenue Forecast: - 2023: 1,347 million yuan - 2024E: 1,554 million yuan (growth rate of 15%) - 2025E: 1,778 million yuan (growth rate of 14%) - 2026E: 2,048 million yuan (growth rate of 15%) [13] - Net Profit Forecast: - 2023: 168 million yuan - 2024E: 200 million yuan (growth rate of 19%) - 2025E: 230 million yuan (growth rate of 15%) - 2026E: 272 million yuan (growth rate of 18%) [13] - Earnings Per Share (EPS): - 2023: 0.41 yuan - 2024E: 0.49 yuan - 2025E: 0.56 yuan - 2026E: 0.67 yuan [13] - Key Financial Ratios: - Gross Margin: Expected to increase from 47.6% in 2023 to 50.0% in 2026 - Net Margin: Expected to improve from 13.3% in 2023 to 14.1% in 2026 - Return on Equity (ROE): Expected to rise from 9.3% in 2023 to 11.8% in 2026 [13].

本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 证券代码：002777 证券简称：久远银海 公告编号：2024-014 四川久远银海软件股份有限公司 第六届董事会第三次会议决议公告 公司严格按照《证券法》、《深圳证券交易所股票上市规则》及《公司章程》等 有关规定和要求，编制完成了《公司 2024 年第一季度报告》（公告编号：2024-013）。 《公司 2024 年第一季度报告》具体内容详见《证券时报》、《证券日报》、《中国 证券报》、《上海证券报》及巨潮资讯网（http://www.cninfo.com.cn）。 表决结果：9 票同意，0 票反对，0 票弃权。该议案已通过。 特此公告。 四川久远银海软件股份有限公司董事会 二〇二四年四月二十四日 一、董事会会议召开情况 四川久远银海软件股份有限公司第六届董事会第三次会议通知于 2024 年 4 月 13 日以专人送达、电话、电子邮件等方式送达全体董事、监事及全体高级管理人员。 会议于 2024 年 4 月 24 日以通讯方式召开，会议应参加表决的董事 9 人，实际参加 表决的董事 9 人。会议由董事长连春华 ...

Revenue and Profitability - The total operating revenue for Q1 2024 was CNY 195,517,542.81, an increase of 4.5% compared to CNY 187,669,914.94 in Q1 2023[15] - The company’s operating revenue for the first quarter was ¥195,517,542.81, representing a 4.18% increase compared to ¥187,669,914.94 in the same period last year[23] - Net profit attributable to shareholders of the listed company decreased by 19.80% to ¥13,433,533.02 from ¥16,749,089.72 year-on-year[23] - The net profit after deducting non-recurring gains and losses was ¥10,175,883.86, down 28.25% from ¥14,183,275.94 in the previous year[23] - Operating profit fell by 47.25% to 10,229,566.96 from 19,393,085.15, mainly due to significant increases in operating costs and selling expenses[26] - Net profit decreased by 48.65% to 8,148,527.36 from 15,868,546.53, primarily due to a reduction in operating profit[26] Costs and Expenses - The total operating costs for Q1 2024 were CNY 183,835,316.02, up 9.8% from CNY 167,447,079.03 in the same period last year[15] - The gross profit margin for Q1 2024 was approximately 6.5%, down from the previous year's margin due to increased operating costs[15] - The company reported R&D expenses of CNY 16,689,326.28 for Q1 2024, a slight decrease from CNY 17,339,969.42 in Q1 2023[15] Cash Flow and Liquidity - Cash and cash equivalents at the end of Q1 2024 were CNY 551,272,503.27, a decrease of 20% from CNY 688,276,391.49 at the beginning of the period[13] - Net cash flow from operating activities improved by 13.45%, amounting to -¥107,768,498.84 compared to -¥124,519,285.98 in the same period last year[23] - Operating cash inflow totaled CNY 199,166,742.58, a decrease of 1.0% from CNY 201,375,898.23 in the previous period[38] - Operating cash outflow amounted to CNY 306,935,241.42, down 5.8% from CNY 325,895,184.21 in the prior period[39] - Cash inflow from investment activities reached CNY 46,402,510.25, significantly up from CNY 10,262,972.50 in the previous period[39] - Cash outflow from investment activities was CNY 71,154,576.65, an increase from CNY 59,183,026.70 in the prior period[39] Assets and Liabilities - The total assets as of the end of Q1 2024 were CNY 2,632,864,126.03, a decrease of 2.7% from CNY 2,706,126,290.19 at the start of the year[14] - The total liabilities at the end of Q1 2024 were CNY 792,786,943.39, down from CNY 873,831,129.08 at the beginning of the period[14] - Total liabilities amounted to CNY 828,252,921.06, down from CNY 909,663,612.58 in the prior period[43] - Total equity reached CNY 1,804,611,204.97, an increase from CNY 1,796,462,677.61 year-over-year[43] Other Financial Metrics - Basic and diluted earnings per share both decreased by 25.00% to ¥0.03 from ¥0.04 year-on-year[23] - The weighted average return on equity was 0.80%, down from 1.08% in the previous year, reflecting a decrease of 0.28%[23] - Shareholders' equity attributable to the listed company increased by 0.80% to ¥1,683,467,745.94 from ¥1,670,034,212.92 year-on-year[23] - The company received government subsidies amounting to ¥2,122,009.82 during the reporting period[23] Changes in Receivables and Inventory - Accounts receivable at the end of Q1 2024 stood at CNY 595,366,789.34, slightly down from CNY 596,211,736.96 at the start of the quarter[13] - Accounts receivable decreased to 0.00 from 621,950.00, a reduction of 100.00% due to the maturity of receivables[26] - Inventory increased to CNY 375,257,209.14 in Q1 2024, up 15.3% from CNY 325,336,882.00 at the beginning of the period[13] - Prepayments decreased by 35.25% to 14,225,284.04 from 21,970,820.70, primarily due to a reduction in advance procurement payments[26] Employee Compensation and Other Assets - The company reported a significant decrease in employee compensation payable by 31.58% to 79,188,869.74 from 115,733,667.78, mainly due to reduced performance payments[26] - The company’s other non-current assets increased by 82.50% to 28,000,000.00 from 15,342,684.93, primarily due to growth in time deposits[26]